Press Releases | BioNTech

7 April 2024

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Read on

20 March 2024

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Read on

20 March 2024

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Read on

11 March 2024

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Read on

7 March 2024

BioNTech Announces Planned Retirement of Sean Marett

Read on

6 March 2024

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

Read on

12 February 2024

BioNTech Receives Science Based Targets Initiative Validation for Near-term Emissions Reduction Targets

Read on

8 February 2024

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Read on

31 January 2024

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

Read on

22 January 2024

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

Read on

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.